Developer docs
API playgroundTry for free, no card

Search company profiles

Seventure Partners

Full company profile

uuid00002xl

Namestring
Seventure Partners
Legal namestring
Seventure Partners (Société anonyme à Directoire et Conseil de Surveillance)
Websiteurl
seventure.fr
Company typeenum
Private
Founded yearint
1997
Descriptiontext

Seventure Partners is a Paris-headquartered European venture capital firm founded in 1997 and operating as a wholly owned subsidiary of Natixis Investment Managers, which in turn sits within Groupe BPCE, a major French banking group. The firm invests across two principal franchises — Life Sciences and Digital Technologies — and manages approximately €1 billion in assets under management as of June 30, 2024. Seventure is staffed by 20+ employees including 26 investment professionals (10 of whom are Venture Partners) and maintains offices in Paris, Munich, London, Geneva, and Basel, with investment activity spanning Europe, North America, Israel, and Asia. As a regulated French portfolio management company (AMF approval GP 01-040), the firm operates on a Limited Partnership model with capital pooled across multiple thematic fund vehicles.

The firm runs a multi-vehicle thematic platform rather than a single diversified fund. The Life Sciences franchise is anchored by the Health for Life Capital™ vehicles (HFLI at €160M, HFLII targeting €200M+, oversubscribed at time of disclosure) — described as the first European vehicles dedicated to financing the microbiome revolution in health and nutrition, backed by strategic LPs including Danone, Novartis, Bel, Lesaffre, Adisseo, and Tereos. Digital Technologies exposure is delivered through the Digital Opportunities Fund, the Sport & Performance Capital vehicle (~€80M, launched with Caisse d'Epargne as Premium Partner of the Paris 2024 Olympics), the Blue Forward Fund (blue economy, SFDR Article 9), AVF (animal health and AgTech, backed by Adisseo), the Quadrivium 1 seed fund (€56.1M with 12 French academic partners including UPMC, CNRS, and Institut Curie), and retail FCPI vehicles (Vie Numérique & Santé 2022-2023 and 2024-2025) that offer French individual investors a 20% income tax reduction. Portfolio scale spans 150+ historical exits including AAA (sold to Novartis for $3.9B) and Santaris (sold to Roche for $250-450M).

The business model rests on three revenue streams: (1) recurring fund management fees, typically 2% of committed and deployed capital across the firm's multiple fund vehicles; (2) carried interest on fund returns above preferred-return hurdles, evidenced by the historical SPEF Pre-IPO fund's 31% reported IRR; and (3) capital gains on direct balance-sheet co-investments. Seventure's LP base is concentrated among strategic corporates and institutional partners, the firm's tickets range from €1-5M per round (digital) to €1-10M initial tickets with up to €20M follow-on capacity per company (life sciences), and the firm holds UNPRI signatory status (2016), France Invest Charter membership (2017), and SFDR Article 8/9 classifications across multiple funds.

Short descriptiontext

Seventure Partners is a Paris-based European venture capital firm founded in 1997, managing ~€1 billion in AUM across Life Sciences and Digital Technologies. A Natixis Investment Managers subsidiary (Groupe BPCE), it operates thematic funds in microbiome, sport, blue economy, and digital innovation.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
venture capital, life sciences investing, digital technology investment, microbiome investment, private equity funding
Industry1 code
PRIMARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)
NAICS code3 codes
  • Portfolio Management and Investment Advice523940
  • Portfolio Management and Investment Advice52394
  • Other Financial Investment Activities5239
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital and Private Equity Fund Management
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Fund management fees
TypeSubscription Recurring
Description

Recurring management fees charged on committed and deployed capital across the firm's multiple fund vehicles (Health for Life Capital I & II, Digital Opportunities Fund, Quadrivium 1, Sport & Performance Capital, etc.) — typical 2% annual management fee on committed/invested capital.

seventure.fr
2Carried interest (performance fees)
TypeUsage Based
Description

Performance-based carried interest on fund returns above preferred return hurdles (historical SPEF Pre-IPO fund reported 31% IRR). Sourced from successful exits and IPOs across the 150+ exit portfolio.

seventure.fr
3Capital gains on direct balance-sheet investments
TypeTransaction Fee
Description

Realized and unrealized gains from the firm's balance-sheet co-investments alongside fund vehicles and historical exits (e.g., Santaris sold to Roche for $250-450M, AAA sold to Novartis for $3.9B, Conject sold to Aconex for €65M).

seventure.fr
Cost components5 values
Personnel, Operations, Marketing or Sales, Others, Technology or R&D
Pricing details3 tiers
1Digital Technologies investment tickets
ModelOtherBilling cadenceMulti-year contract
Notes

Typical ticket sizes of 1–5 million euros per round, with total exposure of up to 10 million euros per portfolio company across rounds.

seventure.fr
2Life Sciences investment tickets
ModelOtherBilling cadenceMulti-year contract
Notes

Initial ticket sizes of 1–10 million euros per round, with follow-on capacity up to 20 million euros per company over the holding period, deployed across Seed to Series C.

seventure.fr
3Retail investor access via FCPI vehicle
ModelOne time/ perpetual licenseBilling cadenceMulti-year contract
Notes

French FCPI (Fonds Commun de Placement dans l'Innovation) vehicle available to individual investors with French tax-advantaged status; minimum subscription amounts per the regulatory prospectus.

seventure.fr
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 6 records shown
1Health for Life Capital™
Description

Venture fund dedicated to health, life sciences, nutrition, and digital health investments.

+5 more records
Core offering1 text field

Seventure Partners is a European venture capital firm that manages multiple thematic funds investing in early-to-growth stage companies across two principal franchises: Life Sciences (microbiome, nutrition, health, medical devices, animal health) and Digital Technologies (fintech, retailtech, sportech, blue economy). Capital is deployed through institutional vehicles (Health for Life Capital™, Digital Opportunities Fund, Sport & Performance Capital™, Blue Forward Fund™, AVF, Quadrivium 1) and retail FCPI products, with typical tickets of €1–10M per round and follow-on capacity up to €10–20M per company. The firm is AMF-approved (GP 01-040) and operates as a wholly owned subsidiary of Natixis Investment Managers.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Seventure Partners is a European venture capital firm (founded 1997, €1bn under management as of 30 June 2024) that operates a multi-fund platform for financing innovative growth companies in two principal domains — Life Sciences and Digital Technologies — plus dedicated thematic franchises for sport, blue economy, animal health and academic seed. The platform is anchored by thematic institutional funds including Health for Life Capital™ (microbiome in health and nutrition, with strategic LPs Danone, Novartis, Bel, Tereos, Tornier, Lesaffre), Digital Opportunities Fund (fintech, retailtech, and other digital innovations in France and Germany), Sport & Performance Capital (~€80M sport economy and well-being fund launched with Caisse d'Epargne), Blue Forward Fund (blue economy), AVF (animal health, feed, nutrition and AgTech, backed by Adisseo), and Fonds d'Amorçage Quadrivium 1 (€56.1M seed fund for French academic spinouts). These institutional vehicles are complemented by retail products such as the Vie Numérique & Santé 2022-2023 FCPI, which provides individual investors a 20% income tax reduction in exchange for investment in digital and life sciences innovation. Seventure Partners is a subsidiary of Natixis Investment Managers and is approved by the French AMF (Autorité des Marchés Financiers) under number GP 01-040.

Product and service7 records
1Health for Life Capital™
CategoryInstitutional Fund (Life Sciences)
Description

European investment vehicles (Health for Life Capital™ I at €160M and Health for Life Capital™ II targeting €200M+) investing in microbiome innovation in health and nutrition, with strategic LPs including Danone, Novartis, Bel, Tereos, Tornier, and Lesaffre. First European vehicles dedicated to financing the microbiome revolution in health and nutrition. Targets Seed to Series C investments with initial ticket sizes of €1-10M and follow-on capacity up to €20M per company.

2Digital Opportunities Fund
3Sport & Performance Capital™
CategoryInstitutional Fund (Sport & Performance)
Description

Thematic institutional venture fund of approximately €80M targeting the French sport and well-being economy, investing in sport-health, equipment, nutrition, IoT-digital, and sport practice innovations. Launched with the support of Caisse d'Epargne. Classified under SFDR Article 8.

4Blue Forward Fund™
CategoryInstitutional Fund (Blue Economy)
Description

Institutional venture capital fund focused on the Blue Economy sectors including sustainable aquaculture, nutrition-cosmetic-health, industrial products and biomaterials, biopolymers and biopackaging, blue digitalization, recycling, climate and carbon, and bioenergies/hydrogen. Classified under SFDR Article 9.

5AVF
CategoryInstitutional Fund (Animal Health)
Description

Seventure-affiliated venture fund brand focused on animal health, feed, nutrition and AgTech, backed by Adisseo as a strategic LP.

6Fonds d'Amorçage Quadrivium 1
CategoryInstitutional Seed Fund (Academic)
Description

€56.1M seed fund created in November 2013 for French seed-stage companies linked to 12 academic and university partners in digital technologies and life sciences (excluding microbiome).

7Vie Numérique & Santé 2022-2023 FCPI
CategoryRetail Fund (FCPI)
Description

French FCPI (Fonds Commun de Placement dans l'Innovation) vehicle available to individual French tax-resident investors, offering a 20% income tax reduction in exchange for investment in innovative companies in digital technologies and life sciences (health, food, work, security, mobility, habitat). Subscriber funds are locked until at least 31 December 2030. Classified under SFDR Article 8.

Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Paris-based private equity and venture capital firm (formerly Edmond de Rothschild Investment Partners) with dedicated life sciences (Andera Life Sciences / BioDiscovery) and digital growth strategies; comparable to Seventure as a French-anchored multi-thematic platform.

TypeBroad incumbent
Description

France's public investment bank, a major French VC and growth investor across digital and life sciences; broader incumbent that co-invests alongside Seventure (e.g., ErVimmune, Karmen) and competes for the same French innovation pipeline.

TypeDirect peer
Description

European healthcare-focused venture and growth capital firm (Utrecht, Netherlands) investing in medtech, digital health, therapeutics and specialty care; direct competitor in the European life sciences/healthtech VC space where Seventure's HFL franchise operates.

TypeDirect peer
Description

Paris- and Singapore-based cross-border venture and growth capital firm investing in digital technologies and healthcare between Europe, North America and Asia; comparable to Seventure in its pan-European/Asian orientation and dual digital/life-sciences thesis.

TypeBroad incumbent
Description

Paris-headquartered European investment firm with private equity, venture and growth strategies including a healthcare-focused franchise; comparable as a large French-anchored multi-thematic investor, though operating at a significantly larger scale than Seventure.

TypeDirect peer
Description

Paris-based European venture capital firm investing across life sciences (biopharma, medtech, digital health) and digital/industrial; the closest French-anchored peer to Seventure with overlapping Life Sciences and Digital mandates and similar ticket sizes.

TypeBroad incumbent
Description

Stockholm-headquartered EQT's venture arm, investing across European digital and life sciences themes at Seed to Growth; broader incumbent comparable to Seventure's full multi-fund platform, though operating at materially larger fund sizes and ticket levels.

TypeDirect peer
Description

London- and San Francisco-based venture capital firm investing across technology and life sciences; comparable to Seventure's Digital Opportunities franchise in stage, ticket size and pan-European digital deal flow.

TypeDirect peer
Description

London-based early-stage venture capital firm investing in European technology startups from Seed to Series A; directly comparable to Seventure's Digital Opportunities Fund in stage focus and pan-European digital-tech thesis.

TypeDirect peer
Description

European life sciences venture capital firm (Naarden, Netherlands) investing Seed to Series C in biopharma and medical devices; directly comparable to Seventure's Health for Life Capital franchise in stage focus, sector specialization and European footprint.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment327 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Seventure Partners

Venture Capital and Private Equity Fund Managementseventure.fr

Seventure Partners is a Paris-based European venture capital firm founded in 1997, managing ~€1 billion in AUM across Life Sciences and Digital Technologies. A Natixis Investment Managers subsidiary (Groupe BPCE), it operates thematic funds in microbiome, sport, blue economy, and digital innovation.

What Seventure Partners does

Seventure Partners is a Paris-headquartered European venture capital firm founded in 1997 and operating as a wholly owned subsidiary of Natixis Investment Managers, which in turn sits within Groupe BPCE, a major French banking group. The firm invests across two principal franchises — Life Sciences and Digital Technologies — and manages approximately €1 billion in assets under management as of June 30, 2024. Seventure is staffed by 20+ employees including 26 investment professionals (10 of whom are Venture Partners) and maintains offices in Paris, Munich, London, Geneva, and Basel, with investment activity spanning Europe, North America, Israel, and Asia. As a regulated French portfolio management company (AMF approval GP 01-040), the firm operates on a Limited Partnership model with capital pooled across multiple thematic fund vehicles.

The firm runs a multi-vehicle thematic platform rather than a single diversified fund. The Life Sciences franchise is anchored by the Health for Life Capital™ vehicles (HFLI at €160M, HFLII targeting €200M+, oversubscribed at time of disclosure) — described as the first European vehicles dedicated to financing the microbiome revolution in health and nutrition, backed by strategic LPs including Danone, Novartis, Bel, Lesaffre, Adisseo, and Tereos. Digital Technologies exposure is delivered through the Digital Opportunities Fund, the Sport & Performance Capital vehicle (~€80M, launched with Caisse d'Epargne as Premium Partner of the Paris 2024 Olympics), the Blue Forward Fund (blue economy, SFDR Article 9), AVF (animal health and AgTech, backed by Adisseo), the Quadrivium 1 seed fund (€56.1M with 12 French academic partners including UPMC, CNRS, and Institut Curie), and retail FCPI vehicles (Vie Numérique & Santé 2022-2023 and 2024-2025) that offer French individual investors a 20% income tax reduction. Portfolio scale spans 150+ historical exits including AAA (sold to Novartis for $3.9B) and Santaris (sold to Roche for $250-450M).

The business model rests on three revenue streams: (1) recurring fund management fees, typically 2% of committed and deployed capital across the firm's multiple fund vehicles; (2) carried interest on fund returns above preferred-return hurdles, evidenced by the historical SPEF Pre-IPO fund's 31% reported IRR; and (3) capital gains on direct balance-sheet co-investments. Seventure's LP base is concentrated among strategic corporates and institutional partners, the firm's tickets range from €1-5M per round (digital) to €1-10M initial tickets with up to €20M follow-on capacity per company (life sciences), and the firm holds UNPRI signatory status (2016), France Invest Charter membership (2017), and SFDR Article 8/9 classifications across multiple funds.

Seventure Partners firmographics

Firmographics
Name
Seventure Partners
Legal name
Seventure Partners (Société anonyme à Directoire et Conseil de Surveillance)
Website
https://seventure.fr
Company type
Private
Founded year
1997
Operating status
Operating
Headcount range
11–50 employees
Short description
Seventure Partners is a Paris-based European venture capital firm founded in 1997, managing ~€1 billion in AUM across Life Sciences and Digital Technologies. A Natixis Investment Managers subsidiary (Groupe BPCE), it operates thematic funds in microbiome, sport, blue economy, and digital innovation.
Ownership category
akta.pro rank

Seventure Partners industry classification

Industry
Product category
Venture Capital and Private Equity Fund Management
NAICS
Portfolio Management and Investment Advice (523940), Portfolio Management and Investment Advice (52394), Other Financial Investment Activities (5239)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)

Keywords

  • Venture capital
  • Life sciences investing
  • Digital technology investment
  • Microbiome investment
  • Private equity funding

Where Seventure Partners is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Markets served

Seventure Partners business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Others, Technology or R&D

Revenue model

  1. Fund management fees: Recurring management fees charged on committed and deployed capital across the firm's multiple fund vehicles (Health for Life Capital I & II, Digital Opportunities Fund, Quadrivium 1, Sport & Performance Capital, etc.) — typical 2% annual management fee on committed/invested capital.
  2. Carried interest (performance fees): Performance-based carried interest on fund returns above preferred return hurdles (historical SPEF Pre-IPO fund reported 31% IRR). Sourced from successful exits and IPOs across the 150+ exit portfolio.
  3. Capital gains on direct balance-sheet investments: Realized and unrealized gains from the firm's balance-sheet co-investments alongside fund vehicles and historical exits (e.g., Santaris sold to Roche for $250-450M, AAA sold to Novartis for $3.9B, Conject sold to Aconex for €65M).

Pricing tiers

ModelBillingPrice
OtherMulti-year contractDigital Technologies investment tickets
OtherMulti-year contractLife Sciences investment tickets
One time/ perpetual licenseMulti-year contractRetail investor access via FCPI vehicle

Go-to-market motion1 record

Seventure Partners product offering

Product offering

Core offering

Seventure Partners is a European venture capital firm that manages multiple thematic funds investing in early-to-growth stage companies across two principal franchises: Life Sciences (microbiome, nutrition, health, medical devices, animal health) and Digital Technologies (fintech, retailtech, sportech, blue economy). Capital is deployed through institutional vehicles (Health for Life Capital™, Digital Opportunities Fund, Sport & Performance Capital™, Blue Forward Fund™, AVF, Quadrivium 1) and retail FCPI products, with typical tickets of €1–10M per round and follow-on capacity up to €10–20M per company. The firm is AMF-approved (GP 01-040) and operates as a wholly owned subsidiary of Natixis Investment Managers.

Product overview

Seventure Partners is a European venture capital firm (founded 1997, €1bn under management as of 30 June 2024) that operates a multi-fund platform for financing innovative growth companies in two principal domains — Life Sciences and Digital Technologies — plus dedicated thematic franchises for sport, blue economy, animal health and academic seed. The platform is anchored by thematic institutional funds including Health for Life Capital™ (microbiome in health and nutrition, with strategic LPs Danone, Novartis, Bel, Tereos, Tornier, Lesaffre), Digital Opportunities Fund (fintech, retailtech, and other digital innovations in France and Germany), Sport & Performance Capital (~€80M sport economy and well-being fund launched with Caisse d'Epargne), Blue Forward Fund (blue economy), AVF (animal health, feed, nutrition and AgTech, backed by Adisseo), and Fonds d'Amorçage Quadrivium 1 (€56.1M seed fund for French academic spinouts). These institutional vehicles are complemented by retail products such as the Vie Numérique & Santé 2022-2023 FCPI, which provides individual investors a 20% income tax reduction in exchange for investment in digital and life sciences innovation. Seventure Partners is a subsidiary of Natixis Investment Managers and is approved by the French AMF (Autorité des Marchés Financiers) under number GP 01-040.

Differentiator

Problem solved

Functional benefit

Brands

  • Health for Life Capital™: Venture fund dedicated to health, life sciences, nutrition, and digital health investments.
  • Sport & Performance Capital™
  • Blue Forward Fund™
  • Digital Opportunities
  • Quadrivium
  • AVF

Products and services

  • Health for Life Capital™ European investment vehicles (Health for Life Capital™ I at €160M and Health for Life Capital™ II targeting €200M+) investing in microbiome innovation in health and nutrition, with strategic LPs including Danone, Novartis, Bel, Tereos, Tornier, and Lesaffre. First European vehicles dedicated to financing the microbiome revolution in health and nutrition. Targets Seed to Series C investments with initial ticket sizes of €1-10M and follow-on capacity up to €20M per company.
  • Digital Opportunities Fund
  • Sport & Performance Capital™ Thematic institutional venture fund of approximately €80M targeting the French sport and well-being economy, investing in sport-health, equipment, nutrition, IoT-digital, and sport practice innovations. Launched with the support of Caisse d'Epargne. Classified under SFDR Article 8.
  • Blue Forward Fund™ Institutional venture capital fund focused on the Blue Economy sectors including sustainable aquaculture, nutrition-cosmetic-health, industrial products and biomaterials, biopolymers and biopackaging, blue digitalization, recycling, climate and carbon, and bioenergies/hydrogen. Classified under SFDR Article 9.
  • AVF Seventure-affiliated venture fund brand focused on animal health, feed, nutrition and AgTech, backed by Adisseo as a strategic LP.
  • Fonds d'Amorçage Quadrivium 1 €56.1M seed fund created in November 2013 for French seed-stage companies linked to 12 academic and university partners in digital technologies and life sciences (excluding microbiome).
  • Vie Numérique & Santé 2022-2023 FCPI French FCPI (Fonds Commun de Placement dans l'Innovation) vehicle available to individual French tax-resident investors, offering a 20% income tax reduction in exchange for investment in innovative companies in digital technologies and life sciences (health, food, work, security, mobility, habitat). Subscriber funds are locked until at least 31 December 2030. Classified under SFDR Article 8.

Companies that use Seventure Partners

Customer profile

Ideal customer profiles3 records

Seventure Partners technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Seventure Partners partnerships and signals

Strategic signal

Recent moves10 records

Expansion highlights6 records

Seventure Partners competitors and assessment

Company assessment

Direct peers

  • Andera Partners: Paris-based private equity and venture capital firm (formerly Edmond de Rothschild Investment Partners) with dedicated life sciences (Andera Life Sciences / BioDiscovery) and digital growth strategies; comparable to Seventure as a French-anchored multi-thematic platform.
  • Gilde Healthcare: European healthcare-focused venture and growth capital firm (Utrecht, Netherlands) investing in medtech, digital health, therapeutics and specialty care; direct competitor in the European life sciences/healthtech VC space where Seventure's HFL franchise operates.
  • Cathay Capital: Paris- and Singapore-based cross-border venture and growth capital firm investing in digital technologies and healthcare between Europe, North America and Asia; comparable to Seventure in its pan-European/Asian orientation and dual digital/life-sciences thesis.
  • Sofinnova Partners: Paris-based European venture capital firm investing across life sciences (biopharma, medtech, digital health) and digital/industrial; the closest French-anchored peer to Seventure with overlapping Life Sciences and Digital mandates and similar ticket sizes.
  • Index Ventures: London- and San Francisco-based venture capital firm investing across technology and life sciences; comparable to Seventure's Digital Opportunities franchise in stage, ticket size and pan-European digital deal flow.
  • Balderton Capital: London-based early-stage venture capital firm investing in European technology startups from Seed to Series A; directly comparable to Seventure's Digital Opportunities Fund in stage focus and pan-European digital-tech thesis.
  • Forbion: European life sciences venture capital firm (Naarden, Netherlands) investing Seed to Series C in biopharma and medical devices; directly comparable to Seventure's Health for Life Capital franchise in stage focus, sector specialization and European footprint.

Broad incumbents

  • Bpifrance: France's public investment bank, a major French VC and growth investor across digital and life sciences; broader incumbent that co-invests alongside Seventure (e.g., ErVimmune, Karmen) and competes for the same French innovation pipeline.
  • Eurazeo: Paris-headquartered European investment firm with private equity, venture and growth strategies including a healthcare-focused franchise; comparable as a large French-anchored multi-thematic investor, though operating at a significantly larger scale than Seventure.
  • EQT Ventures: Stockholm-headquartered EQT's venture arm, investing across European digital and life sciences themes at Seed to Growth; broader incumbent comparable to Seventure's full multi-fund platform, though operating at materially larger fund sizes and ticket levels.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Seventure Partners social profiles

Digital presence

Seventure Partners compliance and trust

Trust signal

Compliance7 records

Seventure Partners financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Seventure Partners leadership team

Management profile

Number of profiles

Profiles7 records

Seventure Partners funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Seventure Partners M&A and investment

M&A and investment

M&A

Investments327 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Seventure Partners

What does Seventure Partners do?

Seventure Partners is a European venture capital firm that manages multiple thematic funds investing in early-to-growth stage companies across two principal franchises: Life Sciences (microbiome, nutrition, health, medical devices, animal health) and Digital Technologies (fintech, retailtech, sportech, blue economy). Capital is deployed through institutional vehicles (Health for Life Capital™, Digital Opportunities Fund, Sport & Performance Capital™, Blue Forward Fund™, AVF, Quadrivium 1) and retail FCPI products, with typical tickets of €1–10M per round and follow-on capacity up to €10–20M per company. The firm is AMF-approved (GP 01-040) and operates as a wholly owned subsidiary of Natixis Investment Managers.

Is Seventure Partners a public or private company?

Seventure Partners is a private company. It is classified as corporate owned and is currently operating.

When was Seventure Partners founded?

Seventure Partners was founded in 1997. It employs 11 to 50 people.

Where is Seventure Partners based?

Seventure Partners is headquartered in Paris, France, in the Europe region.

How does Seventure Partners make money?

Three revenue lines are on record. Fund management fees are the primary driver. The others are carried interest (performance fees) and capital gains on direct balance-sheet investments.

Who are Seventure Partners's main competitors?

Direct peers on record are Andera Partners, Gilde Healthcare, Cathay Capital, Sofinnova Partners, Index Ventures, Balderton Capital and Forbion. Broad incumbents are Bpifrance, Eurazeo and EQT Ventures.

Does Seventure Partners have an API?

No public API is recorded for Seventure Partners.

What industry is Seventure Partners in?

Seventure Partners's product category is Venture Capital and Private Equity Fund Management. Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists). Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SiliconluxembourgANote Music Raises €2M To Scale RoyaltiesANote Music closed a €2M round led by Seventure Partners and ScaleFund to list more catalogues and reach European investors. The company now covers 35 catalogues and 52,000 accounts, with over €28 million traded. Co-founders are assessing a return under EU MiCA rules.Global VenturingHackuity raises $19m as AI drives new wave of vulnerabilitiesHackuity, a French cybersecurity firm, raised $19m in a round led by Forgepoint Capital International, bringing total funding to $38m. The company's platform prioritizes vulnerabilities, claiming to reduce critical-vulnerability noise to 0.01% and cut remediation time by three times. The funding will support international growth and platform development.Pulse 2.0Hackuity Raises $19 Million For AI-Powered Vulnerability ManagementHackuity raised $19 million in new funding led by Forgepoint Capital International, bringing total funding to $38 million. The company will use the capital to accelerate AI capabilities and international growth, aiming to reduce critical vulnerability noise to 0.01% and automate up to 70% of exposure-management activities.Tech.euHackuity secures $19M to address rising AI-driven security vulnerabilitiesHackuity raised $19 million in funding led by Forgepoint Capital International, bringing total funding to $38 million. The company's vulnerability management platform consolidates findings from over 130 security tools and prioritizes remediation. The investment will support product development, AI capabilities, and international expansion in Europe and Asia.GlobalfintechseriesWultra Raises €6.8 Million in Series A Funding to Accelerate Global Expansion of Post-Quantum Digital Identity SolutionsWultra raised €6.8 million in Series A funding led by Seventure Partners to expand its post-quantum digital identity platform. The company will use the funds to scale operations, grow its team, and target large strategic customers, with plans to enter the Middle East and the United States.PR NewswireWultra Raises €6.8 Million in Series A Funding to Accelerate Global Expansion of Post-Quantum Digital Identity SolutionsWultra, a European post-quantum authentication provider, raised €6.8 million in Series A funding led by Seventure Partners. The funds will support its Singapore office, platform scaling, and expansion into the Middle East and the United States. The company now serves over 70 clients across 25 countries.PR NewswireWultra Raises €6.8 Million in Series A Funding to Accelerate Global Expansion of Post-Quantum Digital Identity SolutionsWultra raised €6.8 million in Series A funding led by Seventure Partners to expand its post-quantum digital identity platform. The company will use the funds to scale its platform, develop digital identity wallet capabilities, and expand into the Middle East and the United States.FinSMEsWultra Raises €6.8M in Series A FundingWultra, a Prague-based post-quantum authentication provider, raised €6.8M in Series A funding led by Seventure Partners. The company will use the funds to scale its digital identity platform and accelerate growth, with plans to expand into the Middle East and the United States.PR NewswireWultra Raises €6.8 Million in Series A Funding to Accelerate Global Expansion of Post-Quantum Digital Identity SolutionsWultra raised €6.8 million in Series A funding led by Seventure Partners to expand its post-quantum digital identity platform. The company will use the funds to scale operations, support team growth, and target large strategic customers, with plans to enter the Middle East and the United States.StartupriseWultra Raises €6.8 Mn in Series A Round led by Seventure PartnersWultra, a Prague-based digital identity and post-quantum security solutions provider for banks and fintech companies, has raised €6.8 million in a Series A funding round led by Seventure Partners, with participation from ARIADNEXT founders Marc Norlain and Guillaume Despagne, as well as existing investors J&T Ventures and Elevator Ventures. The company will use the funding to expand its platform and accelerate development of digital identity wallet features supporting the European Digital Identity Wallet initiative. Wultra reported significant growth in 2023, expanding its product portfolio beyond authentication to cover the broader digital identity journey, growing its team by nearly 50%, establishing a presence in Singapore, and now supporting more than 70 clients across 25 countries worldwide.